SecBot SecBot

DNA

Ginkgo Bioworks Holdings, Inc.
NYSE· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001830214 Genomics & Gene Editing
$8.50 −1.11 (−11.55%)
Nov 16 4:00 PM ET · prev $9.61
Market cap
$661.9M
Small cap
Consensus
Sell
0% Buy or better · 10 analysts
Median target
$8.00
−6% · range $5.00–11.00
1 year
+9.3%
from $7.78 · Nov 17
30 days
−15.6%
from $10.07
52-week range
$5.48–14.98
−43% from high · low Mar 30
Avg volume 20D
2.52M
shares / day
Short interest
9.49M
≈14.8% of shares · +14.4%
Days to cover
3.9
at average volume
Insider net
−$2.4M
0 buyers · 5 sellers · since Apr 10
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 0 bearish · 0 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 5/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $2.4M.

  • InstitutionsBULLISH

    Q3 2026: 21 added (0 new), 11 trimmed or exited.

  • AnalystsBEARISH

    0 of 10 rate it Buy or better. Median target $8.00 (−6%).

  • Short sellersSTEADY

    Short interest +14.4% to 9.49M shares. 3.9 days to cover, ≈14.8% of shares.

  • TrendDOWNTREND

    18% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 9.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD PORTFOLIO MANAGEMENT LLCADD1,457,573$18.7M
BARCLAYS PLCDOUBLED511,416$6.6M
DIMENSIONAL FUND ADVISORS LPADD471,921$6.1M
MORGAN STANLEYADD211,431$2.7M
Walleye Capital LLCDOUBLED158,116$2.0M
FRANKLIN TEMPLETON INCDOUBLED168,198$2.0M
PANAGORA ASSET MANAGEMENT INCADD142,625$1.8M
SIMPLEX TRADING, LLCDOUBLED84,325$1.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Sell 0% rate it Buy or better
Strong Buy0Buy0Hold3Sell4Strong Sell3
12-month targets · 2 analysts

Price is inside the target range. Median implies −6%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 13, 2026TD Cowen
MAINTAIN
MAINTAINHold
Sep 4, 2026BTIG
REITERATE
REITERATESell
Aug 7, 2026TD Cowen
DOWNGRADE
DOWNGRADEHold
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 5, 2026
Earnings result
DNA Q3 2026 Earnings: EPS $-0.64 (+27.2% vs est)
Aug 31, 2026
Short interest
Short Interest: DNA up 23% to 6.9M shares
Settlement 2026-08-31 | Days to cover: 5.49 | ≈10.67% of shares outstanding (est.)
May 7, 2026
Earnings date
DNA Q1 2026 Earnings Scheduled, 2026-05-07
Apr 17, 2026
Short interest
FTD: DNA, 75,387 shares ($0.6M) failed to deliver
Settlement: 20260417, Price: $7.95, FTD Value: $599,326.65, GINKGO BIOWORKS HLDGS INC CL A
Mar 3, 2026
Short interest
FTD: DNA, 84,710 shares ($0.6M) failed to deliver
Settlement: 20260303, Price: $7.05, FTD Value: $597,205.5, GINKGO BIOWORKS HLDGS INC CL A

Insider ledger

Form 4
$0
bought · 0 insiders
$2.4M
sold · 5 insiders
DateInsiderTypeValue
Oct 19, 2026
Canton Barry
10%+ Owner
Oct 19, 2026
SELL$190.7K
Oct 19, 2026
Coen Steven P.
See remarks
Oct 19, 2026
SELL$7.8K
Oct 19, 2026
Canton Barry
10%+ Owner
Oct 19, 2026
SELL$226.9K
Oct 19, 2026
Shetty Reshma P.
See remarks
Oct 19, 2026
SELL$226.9K
Oct 19, 2026
Shetty Reshma P.
See remarks
Oct 19, 2026
SELL$190.7K
Oct 19, 2026
Kelly Jason R
See remarks
Oct 19, 2026
SELL$463.4K
Oct 16, 2026
Coen Steven P.
See remarks
Oct 16, 2026
EXERCISE312 sh
Oct 16, 2026
Canton Barry
10%+ Owner
Oct 16, 2026
EXERCISE10,619 sh

Earnings setup

Estimates
−$0.82
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.82-$0.82–-$0.82No data$22.8M
Next Q-$1.05-$1.05–-$1.05No data$22.1M
Current FY-$3.20-$3.20–-$3.20+0.0%$90.1M
Next FY-$2.90-$2.90–-$2.90+9.7%$96.9M

Short side

FINRA· Oct 30, 2026
9,490,310
shares short
+14.4%
vs prior settlement
3.9
days to cover
≈14.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 5, 2026 SEC
Ginkgo Bioworks reported Q3 2026 revenue of $28M (down 6% YoY but up from $20M in Q2), GAAP net loss from continuing…
8-K · Impact 5/10
Nov 5, 2026 Earnings result
DNA Q3 2026 Earnings: EPS $-0.64 (+27.2% vs est)
Oct 29, 2026 SEC
Ginkgo Bioworks filed an 8-K announcing the date of its Q3 2026 earnings presentation and Q&A session, scheduled for…
8-K · Impact 2/10
Oct 21, 2026 SEC
Two insiders at Ginkgo Bioworks sold a combined $198K in open-market sales on October 19, 2026. The selling is…
CLUSTER · Impact 2/10
Oct 19, 2026 Insider
Canton Barry sold 18,803 shares
10%+ Owner @ $10.14 ($190.7K)
Oct 19, 2026 Insider
Coen Steven P. sold 766 shares
See remarks @ $10.14 ($7.8K)
Oct 19, 2026 Insider
Canton Barry sold 22,369 shares
10%+ Owner @ $10.14 ($226.9K)
Sep 30, 2026 Inst.
VANGUARD PORTFOLIO MANAGEMENT LLC · ADD
1,457,573 shares ($18.7M)
Reddit
Recent posts
All social signals and their track records

SecBot reports

7 filings · 0 bullish · 2 bearish · 5 neutral
All DNA filing & press-release reports (7)